Gelonghui, May 9th, Kaneng Health (300272)247slots.SZ) publish an announcement on abnormal volatility in stock trading247slotsThe company's stock trading price for three consecutive trading days (May 7, 2024 to May 9, 2024) closed with a cumulative deviation of more than 30%. According to the relevant provisions of the Trading rules of Shenzhen Stock Exchange, it belongs to the case of abnormal fluctuations in stock trading.

The board of directors of the company confirmed that as of the date of disclosure of the announcement, the company does not have any matters that should be disclosed but not disclosed, such as the rules on the listing of stocks on the growth Enterprise Market of the Shenzhen Stock Exchange, or planning, negotiation, intention, agreement, etc. The board of directors also did not know that the company has information that should be disclosed but not disclosed in accordance with the rules governing the listing of stocks on the gem of the Shenzhen Stock Exchange, which has a greater impact on the trading price of the company's shares; there is no need to correct or supplement the information disclosed in the previous period of the company.

Special risk tips: 1, the company's main business for the whole house water purifier, whole house water softener, commercial purification drinking machine, RO membrane reverse osmosis water purifier, multi-channel control valves, composite pressure vessels, membrane components and other residential water treatment products and core components of research and development, manufacturing, sales and services, the company's business conditions are normal, the main business has not changed. 2. Yuaneng Group is a shareholding enterprise of the company and is not included in the scope of the consolidated statement. 3. Up to now, in the field of stem cell therapy, Yuantian Biological and Medical Research Institution, a subsidiary of Yuaneng Group, is still in the stage of cooperative research and development, has not yet formed operating income, and is not expected to form operating income in 2024, which has no impact on the company's operating performance.